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INTRODUCTION AND OBJECTIVES 
Once an infection has begun to resolve and a patient no longer 
requires hospitalization, except to complete a course of antibiotic 
therapy, continued antibiotic therapy at home should be considered. 
However, patients are often required to remain in the hospital 
because their antibiotics must be administered parenterally for 
therapeutic reasons or lack of an oral dosage form. This is often 
the case in patients with cystic fibrosis being treated for pulmonary 
exacerbations of the disease. Cystic fibrosis, transmitted as an 
autosomal recessive trait, is a disease of the exocrine glands. Pul-
monary involvement is one of the clinical hallmarks in cystic fibrosis 
and is responsible for 95 percent of the morbidity and mortality. The 
viscid mucous secretions favor bacterial growth and three bacterial 
pathogens are frequently isolated in the sputum: Staphylococcus aureus, 
Haemophilus influenzae or Pseudomonas aeruginosa (1). Current treat-
ment of the pulmonary exacerbations in cystic fibrosis caused by 
pulmonary infection often requires hospital admission for aggressive 
chest percussion, postural drainage and treatment with intravenous 
antibiotics (1). Intravenous antibiotics are generally needed for 10 
or more days and usually include an aminoglycoside. Frequently, 
cystic fibrosis patients respond rapidly to treatment but require 
prolonged hospitalization in order to complete the full aminoglyco-
side antibiotic regimen by rate-control!ed intravenous infusion. This 
extended hospital stay results in considerable expense. 
Outpatient intramuscular injections of aminoglycoside would be 
an alternative to inpatient administration of the antibiotic but 
several limitations exist. Intramuscular injections of an aminogly-
coside are less desirable because of discomfort of the injection and 
the lack of injection sites due to the small muscle mass of cystic 
fibrosis patients. Peak serum concentrations reached after intramus-
cular injection would not be expected to be as high as those produced 
by intravenous administration. Theoretically, peak sputum concentra-
tions of antibiotics are related to peak serum concentrations and are 
reached soon after peak levels in the serum after intravenous injec-
tion (2). Pennington and Reynolds have suggested that penetration of 
antibiotics into the lung is greater when there is a large diffusion 
gradient between the serum and sputum and may be achieved if the 
antibiotic is infused over a shorter period of time to allow for 
higher peak concentrations in the serum (2). These higher peak con-
centrations can be achieved with intravenous aminoglycoside infusions 
of 30 to 60 minutes which are theoretically safer than bolus injec-
tion (3). Peak serum concentrations after intramuscular aminogly-
coside injections are generally achieved within 45 to 120 minutes 
(3) and would not provide the same high sputum concentrations as 
would the intravenous routes. Therefore, the outpatient aminoglycoside 
intravenous treatment would be preferred to intramuscular administra-
tion, but requires a safe, ambulatory infusion system which delivers 
the medication at a controlled rate of infusion. 
Parenteral antibiotics have been successfully administered on an 
outpatient basis. The antibiotics have been given by slow intravenous 
push through a heparin lock in cystic fibrosis patients and by small 
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volume intravenous solutions to patients with osteomyelitis, endocar-
titis, septic arthritis, pyelonephritis, blastomycosis, actinoniycosis 
and bacteremia (4-9). These patients received the antibiotics over 2 
to 49 days without meaningful complications. The average cost sav-
ings reported in five of the studies were $97.00 (8), $1,619.80 (5), 
$2,371.00 (9), $2,885.44 (5) and $3,700.00 (4) per patient when com-
pared to the cost that would have been incurred had the patients 
remained hospitalized. 
Administration of parenteral fluids can be accomplished with a 
variety of infusion pumps and controllers (10, 11). Controllers work 
by gravity and count drops electronically or expel volumes of fluid 
mechanically or electronically. Infusion pumps mobilize fluid through 
the intravenous administration tubing against a pressure gradient by 
two mechanisms: 1) piston-cylinder and 2) peristalsis. These types of 
infusion pumps and controllers require electrical.power, intravenous 
fluid bottles and tubing which often limit ambulation. 
Syringe pumps deliver fluid from a preloaded syringe which is 
inserted into or mechanically attached to a pump. These pumps adminis-
ter small volumes of solution from the syringe by electrically, 
mechanically or battery powered pump. Some syringe pumps are 
battery-powered and therefore portable. Syringe pumps currently 
available include Sage (Sage Instruments, Cambridge, MA), Harvard 
(Harvard Apparatus Co., Inc., Mills, MA), Raze! (Razel Scientific 
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Instruments, Inc., Stamford, CT) and Auto-Syringe (Auto-Syringe 
Inc., Hosksett, NH) pumps. 
A portable small volume system developed by the 3M company 
(St. Paul, MN) delivers small volumes of fluid intravenously from 
syringes at controlled rates of flow. This infusion system consists 
of a calibrated flow-regulating set which includes a five micron 
filter and 30-inch tubing, a mechanically powered infuser (25 x 25 x 5 
cm, 0.45 kg) and uses 10 milliliter plastic syringes. The 3M small 
volume infuser (formerly marketed under the name Medifuse ) is 
reusable. The flow rate is regulated by disposable infusion sets. 
The infuser supplies a constant force to the syringe through this 
preset flow regulator by a spring, thereby precluding the need for an 
electrical power source. 
Bosso evaluated the accuracy and efficacy of the portable Medi-
D 
fuse system in healthy adult volunteers (12) and in neonatal and 
pediatric patients (13). In the former study, 11 healthy adult 
volunteers received up to 10 milliliters of normal saline in 10 hours 
during one phase and up to 12 milliliters in a second phase. The 
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Medifuse system ran within ±7.1 percent of the nominal flow rate of 
1.025 milliliter/hour. A 30 percent incidence of phlebitis consisting 
of pain at the site or pain with erythema occurred. In one part of 
the pediatric study, seven patients with cystic fibrosis received a 
total of 61 doses of an aminoglycoside (tobramycin or amikacin) with 
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the Medifuse system on an ambulatory but inpatient basis. The 
results demonstrated that most doses ran at rates which were within 
± 10 percent of the nominal rate of 10 milliliters/hour with no mal-
function, adverse reactions or other problems occurring. 
At-home administration of an aminoglycoside antibiotic should 
lead to decreased hospital stay, emotional stress associated with 
the hospitalization and cost of treating the frequent pulmonary 
exacerbations of cystic fibrosis. Therefore it would be desirable to 
treat the patient on an outpatient basis with an infusion system that 




Subjects eligible to participate were patients at the University 
of Utah Hospital admitted for pulmonary exacerbations of cystic 
fibrosis. Patients were included if they required aminoglycoside 
antibiotic therapy and if the patient and/or parent(s) were compliant 
with instructions in proper syringe pump system use and data collec-
tion. Informed written consent was obtained from participating 
patients or their parents. A total of 15 patients was evaluated; 
eight males and seven females. The mean age was 15 years with a range 
of three to 30 years. 
Infusion System 
The aminoglycoside antibiotic syringes were prepared by the 
University of Utah Hospital Department of Pharmacy Services Intra-
venous Admixture and Manufacturing Service in the appropriate concen-
tration and volume in 10 milliliter syringes. To prepare the syringe, 
the pharmacist increased the dose to be delivered by 1/7 (to allow 
for drug volume remaining in the line) and added this amount of medi-
cation to the syringe. The dose was then diluted to 8 milliliters 
and a 10 milliliter/hour administration set was attached to the syringe 
and purged of all air. The volume in the syringe was then adjusted to 
7 milliliters. Each syringe with attached set was labeled with the 
patient's name, the medication, the final dose and volume to be 
delivered. 
The syringe, with its attached regulating set, was then ready 
to be placed into the syringe pump. After the regulator set with 
needle was attached to the patient's heparin lock or Hickman cathe-
ter, the infusion of the antibiotic was started. 
Data Collection 
Data concerning the syringe pump were collected in two areas: 
1) infusion rate and 2) problems with the infusion such as adverse 
reactions or pump malfunction. 
Patients and/or parent(s) recorded the fluid volumes remaining 
in the syringe at approximately 5 minute intervals during each infu-
sion on a designated form (Figure 1). After the times and volumes 
were noted, any problems with the infuser or catheter since the last 
infusion were also recorded. Problems with the syringe pump were 
recorded on the same form and subdivided into the categories of 
adverse reaction or malfunction. Space for any additional comments 
was provided. Catheter site reactions were also noted as swelling, 
pain at the site, or other, and any comments again could be noted. 
Data were also gathered regarding inpatient hospital costs such 
as the cost of the hospital room per day and cost of preparation of 
the inpatient intravenous antibiotic solutions. These data were then 
compared to the daily cost of renting a syringe pump and preparation 
of syringes for intravenous outpatient use to calculate the estimated 
cost savings for each patient. Th cost of preparing syringes for 
intramuscular use was also determined for comparative purposes. Drug 
costs were not included as these would be the same regardless of the 
system used. 
Data Analysis 
To determine the observed flow rate for each infusion, linear 
regression analyst was performed. The observed flow rate was com-
pared to the preset flow rate to determine the syringe pump accuracy. 
The observed flow rate was calculated for each infusion along with 
percent error. An overall mean observed flow rate ± standard devia-
tion and percent error ± standard deviation were also calculated. 
Mean flow rates and percent error were also determined for each 
patient. 
RESULTS 
Two hundred forty-two infusions were carried out in 15 patients 
of which 235 generated acceptable data for flow rate determination. 
All patients received the aminoglycoside antibiotic tobramycin except 
one patient (number 15) who received gentamicin. The range of 
aminoglycoside concentrations infused were 4.6 to 20 milligrams/ 
milliliter (32.2 to 140 milligram/dose). 
The antibiotic solutions were administered at a rate of 10 
mi 11iliters/hour. The summary of these data is presented in Table 
I. The mean (± standard deviation) observed flow rate for these 235 
trials was 10.46 ± 1.8 milliliters per hour with a range of 6 to 22.8 
milliliters/hour. The mean percent error (± standard deviation) was 
-0.08 ± 14.36. The mean observed flow rate of all patients' mean 
flow rates was 10.31 ± 1.16 milliliters/hour. Mean observed flow 
rates ranged from 8.06 to 12.6 mi 11iliters/hour. Ten of the 15 mean 
patient infusion trials (67%) were associated with a 10 percent or 
less and 14 of the 15 (93%) were associated with less than a 20 per-
cent error. Fifty-three percent (8 patients) of the 15 mean patient 
infusion trials ran faster than the intended 10 milliliters/hour. 
Thirty-three percent (5 patients) ran slower than 10 milliliters per 
hour, while 13 percent (2 patients) ran at 10 milliliters/hour. 
Patients' intravenous catheters were changed 11 times during the 
study because of clotting problems or phlebitis. Five of the 11 
catheter changes occurred in one patient (number 6) who received a 
total of 95 doses with the syringe pump over 36 days before he 
expired. One intravenous catheter (patient 9) was changed because of 
phlebitis probably due to the antibiotic ticarcillin that the patient 
was also receiving which had been administered in between the syringe 
pump aminoglycoside administrations. 
Catheter site reactions are summarized in Table II. Two patients 
experienced pain at the catheter site during single syringe pump 
infusions. Redness of the vein (phlebitis) occurred in two patients 
and swelling-at the catheter site occurred in one patient during a 
single infusion. All adverse reactions, except for one, resolved 
before the next infusion began. A change of catheter, as mentioned 
above, was required for the one patient who developed redness of the 
vein after ticarcillin administration. A malfunction of syringes 
occurred in two of the 242 trials. In both cases, the medication 
leaked out of the syringe resulting in a observed flow rate of 15 
mil 1iliters/hour in one and no data collection in the other. 
Costs for the inpatient and outpatient aminoglycoside therapy 
were determined. Inpatient costs consisted of the hospital room, 
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intravenous piggyback solution and intravenous tubing. For out-
patients, two categories of patient charges were compared: 1) cost 
of the syringe pump which included the daily rental of a syringe pump, 
preparation of the syringe and intravenous tubing, and 2) cost of the 
preparation of syringes for intramuscular administration. All costs 
were calculated on the basis of 1983 patient charges at the University 
of Utah Hospital and are shown in Table III. 
The average amount saved through the use of the syringe pump was 
$1,121.47 per patient with a range of $375.16 to $6,819.18. The aver-
age amount saved per day was $189.01. If using at home intramuscular 
aminoglycoside administration, the mean saving would have been 
$1,164.05 per patient (range $389.96 to $7,075.18) or $196.19 per day. 
DISCUSSION 
The syringe pump system was found to be a safe and dependable 
method for the outpatient administration of intravenous aminoglycoside 
antibiotics. Only two syringe malfunctions and no pump malfunctions 
were noted. Two patients reported redness of the vein (phlebitis) 
at the intravenous catheter site and pain at the site of the catheter 
also occurred in two different patients. One patient reported swell-
ing at the site of the catheter. All of these adverse reactions 
occurred during one infusion trial except for one in which redness of 
the vein developed after ticarcillin administration. This was a lower 
rate of intravenous therapy induced complications than has been 
reported previously (14). 
The mean observed flow rate and error rate were similar to that 
reported for the MedifuseR system in the pediatric study (13). The 
importance of this variation in observed flow rates will depend upon 
the clinical situation in which the syringe pump is used. With home 
administration of aminoglycoside antibiotics, Bosso has stated that a 
high error rate (20%) is not clinically important (13). Results 
show that except for one patient, all mean patient infusion trials 
ran within 20 percent of the predicted 10 milliliters/hour. 
A syringe pump could be used to administer antibiotics at home 
in other disease states such as osteomyelitis, endocarditis, septic 
arthritis and pyelonephritis. However, such systems might have 
limitations in regard to which antibiotics could be administered 
because of viscosity dependent flow rates and antibiotic concentra-
tion dependent adverse reactions (ie, penicillin-induced phlebitis). 
. There would be a dramatic reduction in patient charges when the 
medications are given at home. The average cost savings per patient 
was $1,121.47 or $189.01 per day. The average outpatient cost savings 
would be slightly more with intramuscular administration, however, 
this route of administration is less desirable. As expected, the 
major savings were in the hospital room costs. The syringe pump is 
more cost effective in addition to being portable and easier to use 
than outpatient intravenous piggyback solutions and pumps. Additional 
cost savings might occur when older patients return to their homes, 
schools and jobs. The syringe pump system therefore appears to be a 
safe and dependable alternative for self-administration of antibio-
tics by outpatients. 
FIGURE 1 
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SYRINGE PUMP DATA 
2 Mean 
Mean R * Observed Mean 
(Regression Flow Rate Percent 
Analysis) (ml/hr) Error 
0.99 10.08 0.80 
0.99 8.57 -14.28 
0.98 10.80 8.00 
0.99 11.51 15.12 
0.99 8.06 -19.42 
0.99 10.66 6.61 
0.99 9.85 - 1.46 
0.97 12.60 26.00 
1.00 10.98 ' 9.80 
0.97 10.90 9.00 
0.99 11.07 10.70 
0.99 9.60 - 4.00 
0.98 10.02 0.20 
0.99 10.87 8.70 
0.99 9.18 - 8.20 
Mean: 16 0.98 10.31 + 3.17 
*Regression Analysis of Actual Flow Rate 
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TABLE II 
ADVERSE REACTIONS SUMMARY 
CATHETER SITE REACTION 
Patient Number Type of Reaction 
1 redness of vein 
6 pain at site 
8 swelling 
9 redness of vein (due to ticarcillin) 




Number Antibiotic Total Total 
of Treatment Syringe Pump Intramuscular 
Patient Doses Duration (days) Cost ($) Cost ($) 
1 10 4 71. .00 43.00 
2 7 3 50. 70 30.10 
3 7 3 50. 70 30.10 
4 16 7 116. .60 68.80 
5 9 3 60. 90 38.70 
6 95 36 664. ,50 408.50 
7 26 7 167. ,60 111.80 
8 9 3 60. .90 38.70 
9 10 4 71. .00 43.00 
10 6 2 40. .60 25.80 
11 9 3 60. .90 38.70 
12 9 3 60. .90 38.70 
14 10 4 71. .00 43.00 
15 9 3 60. .90 38.70 





Total Estimated Syringe Pump Cost 
Treatment If Cost Savings Savings 
Hospitalized ($) .. il) 
831.52 760.52 788.52 
623.64 572.94 593.54 
623.64 572.94 593.54 
1455.16 1338.56 1386.36 
623.64 562.74 584.94 
7483.68 6819.18 7075.18 
1455.16 1287.56 1343.36 
623.65 562.74 584.94 
831.52 760.52 788.52 
415.76 375.16 389.96 
623.64 562.74 584.94 
623.64 562.74 584.94 
831.52 760.52 788.52 
623.64 562.74 584.94 
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PROFESSIONAL ORGANIZATIONS 
Utah Society of Hospital Pharmacists, 1982-present 
American Pharmaceutical Association, 1981-1982 
Student American Pharmaceutical Association, 1978-1981 
Michigan Pharmacists Association, 1978-1981 
COMMUNITY SERVICE 
Counselor 
Cystic Fibrosis Camp 
July 3-10, 1982 
Health Screening Pharmacist 
Senior Citizen Health Fair 
March 1982, April 13, 1983, May 14, 1983 
Health Screening Pharmacist 
High Rise Geriatric Center 
October 1981 - present 
